Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML
Novartis has picked up a new drug approval, this time for Rydapt (midostaurin, PKC412) for newly diagnosed cases of acute myeloid leukemia among patients with a specific FLT3 genetic mutation. The drug will be used in combination with a chemotherapy and there’s a diagnostic available to ID the right patients for this drug.
The drug, designated as a breakthrough therapy at the FDA, is a kinase inhibitor that tackles enzymes associated with the advance of the blood cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.